

Giuseppe Curigliano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8033883/publications.pdf>

Version: 2024-02-01

735
papers

42,166
citations

5126

86
h-index

4131

181
g-index

768
all docs

768
docs citations

768
times ranked

41255
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-------|-----------|
| 1 | Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299. | 1.0 | 213 |
| 2 | Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 95-105. | 3.2 | 24 |
| 3 | Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review. <i>Annals of Oncology</i> , 2022, 33, 158-168. | 0.6 | 59 |
| 4 | Advances and controversies in management of breast ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , 2022, 48, 736-741. | 0.5 | 10 |
| 5 | Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182. | 157.7 | 132 |
| 6 | Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174. | 1.3 | 49 |
| 7 | Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72. | 1.1 | 26 |
| 8 | Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324. | 3.4 | 46 |
| 9 | Immuno-oncology trends: preclinical models, biomarkers, and clinical development. , 2022, 10, e003231. | | 20 |
| 10 | Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 629. | 3.4 | 18 |
| 11 | Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 582-593. | 0.5 | 4 |
| 12 | Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354. | 3.4 | 2 |
| 13 | Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001. | | 45 |
| 14 | Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43. | 1.3 | 88 |
| 15 | Global challenges and policy solutions in breast cancer control. <i>Cancer Treatment Reviews</i> , 2022, 104, 102339. | 3.4 | 74 |
| 16 | Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 465-484. | 1.1 | 6 |
| 17 | Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238. | 0.6 | 11 |
| 18 | Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. <i>Annals of Oncology</i> , 2022, 33, 321-329. | 0.6 | 97 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487. | 0.6 | 67 |
| 20 | Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23. | 2.3 | 67 |
| 21 | Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01. | 0.4 | 4 |
| 22 | Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities. <i>Cancer Research</i> , 2022, 82, GS3-03-GS3-03. | 0.4 | 0 |
| 23 | Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022, 82, P4-06-08-P4-06-08. | 0.4 | 0 |
| 24 | Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. <i>Cancer Research</i> , 2022, 82, OT1-02-02-OT1-02-02. | 0.4 | 0 |
| 25 | Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151. | 1.7 | 5 |
| 26 | Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-04-P2-13-04. | 0.4 | 2 |
| 27 | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514. | 1.1 | 7 |
| 28 | Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817. | 1.8 | 35 |
| 29 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154. | 13.9 | 474 |
| 30 | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651. | 1.6 | 63 |
| 31 | CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605. | 1.9 | 31 |
| 32 | Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology</i> , The, 2022, 23, 325-328. | 5.1 | 1 |
| 33 | Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. <i>Cancers</i> , 2022, 14, 1771. | 1.7 | 15 |
| 34 | How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. <i>ESMO Open</i> , 2022, 7, 100428. | 2.0 | 4 |
| 35 | SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207. | 1.3 | 4 |
| 36 | Harmonizing PD-L1 testing in metastatic triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 345-348. | 1.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153. | 1.1 | 5 |
| 38 | Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 79. | 1.7 | 7 |
| 39 | Definition of High-Risk Early Hormone-Positive HER2 ⁻ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898. | 1.7 | 20 |
| 40 | Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395. | 3.4 | 60 |
| 41 | Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. <i>Annals of Oncology</i> , 2022, 33, 845-847. | 0.6 | 5 |
| 42 | Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. <i>Annals of Oncology</i> , 2022, 33, 702-712. | 0.6 | 24 |
| 43 | Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. <i>Breast</i> , 2022, 64, 100-111. | 0.9 | 5 |
| 44 | Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 717-734. | 1.4 | 8 |
| 45 | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 82-92. | 1.8 | 6 |
| 46 | Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 10519-10519. | 0.8 | 0 |
| 47 | Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000. | 0.8 | 9 |
| 48 | Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1112-TPS1112. | 0.8 | 0 |
| 49 | Quantifying geographical accessibility to cancer clinical trials in different income landscapes. <i>ESMO Open</i> , 2022, 7, 100515. | 2.0 | 3 |
| 50 | Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3063-3063. | 0.8 | 0 |
| 51 | Clinical activity of CC-90011 , an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. <i>Cancer</i> , 2022, 128, 3185-3195. | 2.0 | 10 |
| 52 | Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13639-e13639. | 0.8 | 0 |
| 53 | Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. <i>Cancers</i> , 2022, 14, 3193. | 1.7 | 9 |
| 54 | Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2587-2587. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGF β 2 inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2524-2524. | 0.8 | 3 |
| 56 | Pralsetinib in patients (pts) with advanced or metastatic <i>RET</i> -altered thyroid cancer (TC): Updated data from the ARROW trial.. Journal of Clinical Oncology, 2022, 40, 6080-6080. | 0.8 | 5 |
| 57 | Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. Journal of Clinical Oncology, 2022, 40, 3087-3087. | 0.8 | 2 |
| 58 | Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs, 2022, 31, 855-874. | 1.9 | 2 |
| 59 | Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews, 2022, 109, 102434. | 3.4 | 14 |
| 60 | Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer, 2022, 171, 25-42. | 1.3 | 9 |
| 61 | Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. European Journal of Cancer, 2022, 172, 332-339. | 1.3 | 6 |
| 62 | Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 438-446. | 3.2 | 21 |
| 63 | Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487. | 3.3 | 16 |
| 64 | Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 2021, 21, 127-133. | 1.4 | 21 |
| 65 | CDK4/6 inhibitors for HR+HER2 ⁺ early stage breast cancer – when to escalate treatment?. Nature Reviews Clinical Oncology, 2021, 18, 67-68. | 12.5 | 4 |
| 66 | ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Annals of Oncology, 2021, 32, 337-350. | 0.6 | 76 |
| 67 | Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133. | 3.4 | 4 |
| 68 | Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Annals of Oncology, 2021, 32, 113-119. | 0.6 | 51 |
| 69 | New anti-HER2 agents for brain metastasis: histology-agnostic weapons?. Breast Cancer Research and Treatment, 2021, 185, 879-881. | 1.1 | 3 |
| 70 | Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2021, 39, 87-87. | 0.8 | 0 |
| 71 | Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer Journal (Sudbury, Mass), 2021, 27, 41-49. | 1.0 | 26 |
| 72 | Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28. | 5.1 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Clinical development and current role of margetuximab for the treatment of breast cancer. <i>Drugs of Today</i> , 2021, 57, 551. | 0.7 | 3 |
| 74 | Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9-9. | 0.8 | 69 |
| 75 | The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155. | 3.0 | 13 |
| 76 | Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467. | 0.8 | 16 |
| 77 | Antibody-drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021, 14, 20. | 6.9 | 129 |
| 78 | Abstract PS2-11: Ctc-her2+ a novel subset in stage IVaggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer. <i>Cancer Research</i> , 2021, 81, PS2-11-PS2-11. | 0.4 | 3 |
| 79 | Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583. | 1.7 | 13 |
| 80 | Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 885-886. | 1.1 | 3 |
| 81 | Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172. | 0.8 | 38 |
| 82 | Abstract PS2-15: The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer. <i>Cancer Research</i> , 2021, 81, PS2-15-PS2-15. | 0.4 | 2 |
| 83 | Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReEnd trial. <i>Breast Cancer Research</i> , 2021, 23, 38. | 2.2 | 14 |
| 84 | PIK3CA Mutation Assessment in HR+/HER2- Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021, 2, 42-54. | 0.5 | 9 |
| 85 | The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169. | 3.4 | 14 |
| 86 | Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209. | 1.3 | 16 |
| 87 | Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103223. | 2.0 | 52 |
| 88 | Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455. | 3.2 | 4 |
| 89 | 70 Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). <i>Annals of Oncology</i> , 2021, 32, S4. | 0.6 | 0 |
| 90 | COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319. | 12.5 | 103 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Accelerating progress from advanced to early breast cancer for TNBC. <i>Breast</i> , 2021, 56, S10. | 0.9 | 0 |
| 92 | Commentary: SARS-CoV-2 vaccines and cancer patients. <i>Annals of Oncology</i> , 2021, 32, 569-571. | 0.6 | 43 |
| 93 | Phase I/IIb Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3620-3629. | 3.2 | 151 |
| 94 | Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501. | | 18 |
| 95 | Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573. | 3.4 | 217 |
| 96 | Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160. | 0.9 | 25 |
| 97 | SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327. | 1.3 | 55 |
| 98 | Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 323-337. | 1.1 | 15 |
| 99 | Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2564-2564. | 0.8 | 25 |
| 100 | 26P Characterization of low HER2 expressions in de-novo metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, S31. | 0.6 | 1 |
| 101 | A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2624-2624. | 0.8 | 10 |
| 102 | Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase III trial. <i>European Journal of Cancer</i> , 2021, 148, 382-394. | 1.3 | 22 |
| 103 | 24P Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer clinicians: The PROCURE project. <i>Annals of Oncology</i> , 2021, 32, S30-S31. | 0.6 | 0 |
| 104 | 8P Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial. <i>Annals of Oncology</i> , 2021, 32, S24. | 0.6 | 0 |
| 105 | Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021, 155, 127-135. | 0.9 | 6 |
| 106 | Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1043-1043. | 0.8 | 9 |
| 107 | Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769. | 6.3 | 731 |
| 108 | Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145. | 1.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. <i>European Journal of Cancer</i> , 2021, 148, 277-286. | 1.3 | 7 |
| 110 | Safety and efficacy of pralsetinib in patients with advanced <i>RET</i> fusion-positive non-small cell lung cancer: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9089-9089. | 0.8 | 9 |
| 111 | SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2657-TPS2657. | 0.8 | 4 |
| 112 | KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2626-2626. | 0.8 | 0 |
| 113 | Clinical activity and safety of the <i>RET</i> inhibitor pralsetinib in patients with <i>RET</i> fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3079-3079. | 0.8 | 6 |
| 114 | Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIV _{aggressive} breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3036-3036. | 0.8 | 3 |
| 115 | Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152. | 1.3 | 41 |
| 116 | Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!. <i>European Journal of Cancer</i> , 2021, 153, 257-259. | 1.3 | 12 |
| 117 | Antibody-Drug Conjugates for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 2898. | 1.7 | 34 |
| 118 | Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354. | 2.0 | 15 |
| 119 | COVID-19 vaccines in patients with cancer. <i>Lancet Oncology</i> , The, 2021, 22, 738-739. | 5.1 | 16 |
| 120 | Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , 2021, 6, 100106. | 2.0 | 9 |
| 121 | Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117. | 2.0 | 37 |
| 122 | The global landscape of drug development of trastuzumab biosimilars. <i>Journal of Cancer Policy</i> , 2021, 28, 100273. | 0.6 | 3 |
| 123 | Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205. | 3.4 | 21 |
| 124 | The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167. | 1.3 | 45 |
| 125 | Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11. | 1.0 | 15 |
| 126 | The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. <i>Journal of Cancer Policy</i> , 2021, 28, 100285. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncology Practice, 2021, 17, 605-606. | 1.4 | 6 |
| 128 | Association of Breast Cancer Irradiation With Cardiac Toxic Effects. JAMA Oncology, 2021, 7, 924. | 3.4 | 17 |
| 129 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811. | 7.7 | 79 |
| 130 | Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. International Journal of Cancer, 2021, 149, 1455-1462. | 2.3 | 16 |
| 131 | SY16-1 Advances in early breast cancer (EBC) care from the perspective of escalation and de-escalation. Annals of Oncology, 2021, 32, S260. | 0.6 | 0 |
| 132 | SO-9 Analysis of the immune-related endpoints of the mismatch repair-deficient non-endometrial solid cancers cohort from the GARNET study. Annals of Oncology, 2021, 32, S205-S206. | 0.6 | 0 |
| 133 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969. | 5.1 | 222 |
| 134 | Precision medicine in breast cancer: From clinical trials to clinical practice. Cancer Treatment Reviews, 2021, 98, 102223. | 3.4 | 34 |
| 135 | Alpelisib in combination with everolimus±Aexemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62. | 1.3 | 19 |
| 136 | Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European Journal of Cancer, 2021, 153, 162-167. | 1.3 | 10 |
| 137 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Annals of Oncology, 2021, 32, 1496-1510. | 0.6 | 42 |
| 138 | Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Current Oncology, 2021, 28, 3384-3392. | 0.9 | 4 |
| 139 | Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. Journal of Clinical Oncology, 2021, 39, 3541-3545. | 0.8 | 6 |
| 140 | Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370. | | 10 |
| 141 | Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes and Endocrinology,the, 2021, 9, 491-501. | 5.5 | 192 |
| 142 | Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMBtrial). European Journal of Cancer, 2021, 153, 223-233. | 1.3 | 9 |
| 143 | Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals, 2021, 14, 884. | 1.7 | 17 |
| 144 | A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5760-5770. | 3.2 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253. | 3.4 | 26 |
| 146 | 1583P COVID-19 related risk in patients enrolled in early-phase clinical trials. <i>Annals of Oncology</i> , 2021, 32, S1140-S1141. | 0.6 | 0 |
| 147 | Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-15. | 1.9 | 8 |
| 148 | The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 175-189. | 1.3 | 24 |
| 149 | Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102261. | 3.4 | 7 |
| 150 | A Phase 1â€² Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1559-1569. | 0.5 | 41 |
| 151 | LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. <i>Annals of Oncology</i> , 2021, 32, S1287-S1288. | 0.6 | 64 |
| 152 | Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421. | 1.7 | 12 |
| 153 | 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) Â± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). <i>Annals of Oncology</i> , 2021, 32, S478-S479. | 0.6 | 2 |
| 154 | 94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations. <i>Annals of Oncology</i> , 2021, 32, S397. | 0.6 | 0 |
| 155 | Biomedical omics: first insights of a new MSc degree of the University of Milan. <i>Tumori</i> , 2021, , 030089162110472. | 0.6 | 1 |
| 156 | 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies. <i>Annals of Oncology</i> , 2021, 32, S615-S616. | 0.6 | 0 |
| 157 | 991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study. <i>Annals of Oncology</i> , 2021, 32, S845-S846. | 0.6 | 0 |
| 158 | Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551. | 0.6 | 36 |
| 159 | Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1233-1252. | 1.3 | 14 |
| 160 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235. | 0.6 | 354 |
| 161 | Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. <i>ESMO Open</i> , 2021, 6, 100237. | 2.0 | 10 |
| 162 | Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. <i>Cancer Treatment Reviews</i> , 2021, 100, 102281. | 3.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. <i>European Journal of Cancer</i> , 2021, 157, 40-49. | 1.3 | 3 |
| 164 | Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873. | 3.4 | 66 |
| 165 | National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. <i>Lancet Oncology</i> , The, 2021, 22, 1632-1642. | 5.1 | 84 |
| 166 | Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021, 13, 5416. | 1.7 | 7 |
| 167 | Precision Cancer Medicine: Large Studies Indicate Steady Progress. <i>Cancer Discovery</i> , 2021, 11, 2677-2678. | 7.7 | 6 |
| 168 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495. | 0.6 | 454 |
| 169 | Distribution of the workforce involved in cancer care: a systematic review of the literature. <i>ESMO Open</i> , 2021, 6, 100292. | 2.0 | 18 |
| 170 | 370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial. , 2021, 9, A398-A398. | | 0 |
| 171 | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. , 2021, 9, e003224. | | 12 |
| 172 | Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 5829. | 1.7 | 8 |
| 173 | Novel immune targets for the treatment of triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 815-834. | 1.5 | 11 |
| 174 | Pan-Asian adaptation of the EHS "ESMO" ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. <i>ESMO Open</i> , 2021, 6, 100309. | 2.0 | 29 |
| 175 | Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. <i>Breast</i> , 2021, , . | 0.9 | 1 |
| 176 | Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100. | 3.4 | 68 |
| 177 | Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209. | 0.9 | 24 |
| 178 | CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. <i>Lancet Oncology</i> , The, 2020, 21, 191-192. | 5.1 | 7 |
| 179 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609. | 13.9 | 789 |
| 180 | 180 CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. <i>Annals of Oncology</i> , 2020, 31, S6. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). <i>Annals of Oncology</i> , 2020, 31, S62-S63. | 0.6 | 0 |
| 182 | Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. <i>European Journal of Cancer</i> , 2020, 139, 92-98. | 1.3 | 12 |
| 183 | Repurposing anticancer drugs for the management of COVID-19. <i>European Journal of Cancer</i> , 2020, 141, 40-61. | 1.3 | 59 |
| 184 | Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. <i>JCO Global Oncology</i> , 2020, 6, 1428-1438. | 0.8 | 189 |
| 185 | Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020, 6, 1461-1471. | 0.8 | 44 |
| 186 | 171P An outcomes summary of the clinical advances curriculum on CDK4 & 6 inhibition in breast cancer. <i>Annals of Oncology</i> , 2020, 31, S77. | 0.6 | 2 |
| 187 | 6P Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC). <i>Annals of Oncology</i> , 2020, 31, S18. | 0.6 | 0 |
| 188 | Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54. | 2.3 | 181 |
| 189 | How to treat lobular cancer in the adjuvant setting?. <i>Current Opinion in Oncology</i> , 2020, 32, 561-567. | 1.1 | 5 |
| 190 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649. | 0.6 | 761 |
| 191 | 36P Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study. <i>Annals of Oncology</i> , 2020, 31, S13. | 0.6 | 0 |
| 192 | 5P Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents. <i>Annals of Oncology</i> , 2020, 31, S1-S2. | 0.6 | 0 |
| 193 | 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). <i>Annals of Oncology</i> , 2020, 31, S1084. | 0.6 | 29 |
| 194 | LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET). <i>Annals of Oncology</i> , 2020, 31, S62. | 0.6 | 9 |
| 195 | Progresses Toward Precision Medicine in RET-altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6102-6111. | 3.2 | 39 |
| 196 | Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. <i>European Journal of Cancer</i> , 2020, 141, 218-224. | 1.3 | 8 |
| 197 | Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446. | 1.8 | 1 |
| 198 | Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1543-1545. | 5.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 693-695. | 13.9 | 16 |
| 200 | Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085. | 3.4 | 41 |
| 201 | Cancer Patients and Risk of Mortality for COVID-19. <i>Cancer Cell</i> , 2020, 38, 161-163. | 7.7 | 47 |
| 202 | Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020, 31, 1320-1335. | 0.6 | 219 |
| 203 | Antibody-drug conjugates in breast cancer: the chemotherapy of the future?. <i>Current Opinion in Oncology</i> , 2020, 32, 494-502. | 1.1 | 25 |
| 204 | P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens. <i>Annals of Oncology</i> , 2020, 31, S115. | 0.6 | 3 |
| 205 | The legacy of Professor Aron Goldhirsch. <i>Annals of Oncology</i> , 2020, 31, 671-673. | 0.6 | 0 |
| 206 | A role for the immune system in advanced laryngeal cancer. <i>Scientific Reports</i> , 2020, 10, 18327. | 1.6 | 14 |
| 207 | Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602. | 1.1 | 6 |
| 208 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793. | 2.0 | 113 |
| 209 | 187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer. <i>Annals of Oncology</i> , 2020, 31, S317-S318. | 0.6 | 0 |
| 210 | 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). <i>Annals of Oncology</i> , 2020, 31, S349-S350. | 0.6 | 4 |
| 211 | 298P Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis. <i>Annals of Oncology</i> , 2020, 31, S362. | 0.6 | 0 |
| 212 | 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study. <i>Annals of Oncology</i> , 2020, 31, S382-S383. | 0.6 | 0 |
| 213 | Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020, 90, 102089. | 3.4 | 27 |
| 214 | Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50. | 1.3 | 267 |
| 215 | Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. <i>Oncologist</i> , 2020, 25, e1732-e1742. | 1.9 | 16 |
| 216 | Management of Cardiac Toxicity Induced by Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2885. | 1.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 217 | Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504. | 157.7 | 29 |
| 218 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243. | 5.1 | 297 |
| 219 | Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020, 5, e001081. | 2.0 | 6 |
| 220 | Implementing clinical practice guidelines: time to assess it. <i>ESMO Open</i> , 2020, 5, e001130. | 2.0 | 0 |
| 221 | 1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies. <i>Annals of Oncology</i> , 2020, 31, S729-S730. | 0.6 | 0 |
| 222 | LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology. <i>Annals of Oncology</i> , 2020, 31, S1205-S1206. | 0.6 | 6 |
| 223 | LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study. <i>Annals of Oncology</i> , 2020, 31, S1206. | 0.6 | 5 |
| 224 | 300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study. <i>Annals of Oncology</i> , 2020, 31, S362-S363. | 0.6 | 2 |
| 225 | 528O CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. <i>Annals of Oncology</i> , 2020, 31, S464. | 0.6 | 0 |
| 226 | 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). <i>Annals of Oncology</i> , 2020, 31, S1413-S1414. | 0.6 | 2 |
| 227 | Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2867-2878. | 1.1 | 8 |
| 228 | Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362. | 0.8 | 16 |
| 229 | Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42. | 0.4 | 15 |
| 230 | Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466. | 1.4 | 16 |
| 231 | Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809. | 1.9 | 26 |
| 232 | Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis. <i>European Journal of Cancer</i> , 2020, 134, 6-8. | 1.3 | 1 |
| 233 | 51P Evolution of low HER2 expressions between primary and metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, S33. | 0.6 | 1 |
| 234 | 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. <i>Annals of Oncology</i> , 2020, 31, S60-S61. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-------|-----------|
| 235 | 151P The landscape of patients with metastatic breast cancer enrolled in phase I trials. <i>Annals of Oncology</i> , 2020, 31, S70-S71. | 0.6 | 0 |
| 236 | In Reply. <i>Oncologist</i> , 2020, 25, e1252-e1253. | 1.9 | 0 |
| 237 | Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. <i>Journal of Clinical Investigation</i> , 2020, 130, e000617. | | 57 |
| 238 | Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020, 11, 2332. | 5.8 | 90 |
| 239 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17. | 2.3 | 106 |
| 240 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619. | 0.8 | 331 |
| 241 | Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427. | 1.9 | 7 |
| 242 | Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , 2020, 123, 694-697. | 2.9 | 37 |
| 243 | Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65. | 1.3 | 32 |
| 244 | Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 381-387. | 0.6 | 3 |
| 245 | Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504. | 0.9 | 3 |
| 246 | A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945. | 1.9 | 520 |
| 247 | Tumor-infiltrating lymphocytes (TILs) in ER+/HER2 ⁻ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 347-354. | 1.1 | 59 |
| 248 | The global landscape of drug development for kidney cancer. <i>Cancer Treatment Reviews</i> , 2020, 89, 102061. | 3.4 | 5 |
| 249 | Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020, 46, 717-736. | 0.5 | 12 |
| 250 | Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22. | 0.4 | 5 |
| 251 | Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124. | 157.7 | 123 |
| 252 | Is Explanation a Marketing Problem? The Quest for Trust in Artificial Intelligence and Two Conflicting Solutions. <i>Public Health Genomics</i> , 2020, 23, 2-5. | 0.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020, 38, 1070-1080. | 0.8 | 19 |
| 254 | Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190. | 0.6 | 582 |
| 255 | Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020, 84, 101963. | 3.4 | 61 |
| 256 | Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. <i>European Journal of Cancer</i> , 2020, 127, 236-239. | 1.3 | 3 |
| 257 | Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139. | 3.2 | 40 |
| 258 | The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. <i>European Journal of Cancer</i> , 2020, 132, 199-206. | 1.3 | 48 |
| 259 | Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 221-224. | 1.1 | 7 |
| 260 | ESOâ€“ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696. | 0.6 | 172 |
| 261 | Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024. | 1.4 | 23 |
| 262 | Master protocols in immuno-oncology: do novel drugs deserve novel designs?. , 2020, 8, e000475. | | 17 |
| 263 | HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962. | 0.8 | 353 |
| 264 | Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> , the, 2020, 7, e432-e435. | 2.2 | 103 |
| 265 | Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020, 52, 8-16. | 0.9 | 188 |
| 266 | Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)â€“related disease pandemic. <i>European Journal of Cancer</i> , 2020, 132, 8-10. | 1.3 | 12 |
| 267 | How can biosimilars change the trajectory of breast cancer therapy?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 325-328. | 1.1 | 12 |
| 268 | Lucitanib for the Treatment of HR+/HER2â€“ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363. | 3.2 | 40 |
| 269 | How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience. <i>Oncologist</i> , 2020, 25, 463-467. | 1.9 | 33 |
| 270 | Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 3-13. | 1.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | 1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study. <i>Annals of Oncology</i> , 2020, 31, S1209-S1210. | 0.6 | 5 |
| 272 | Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). , 2020, , . | | 2 |
| 273 | Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. <i>Cancer Research</i> , 2020, 80, GS1-02-GS1-02. | 0.4 | 24 |
| 274 | Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study). , 2020, , . | | 1 |
| 275 | Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET). , 2020, , . | | 2 |
| 276 | A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1039-1039. | 0.8 | 26 |
| 277 | SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1040-1040. | 0.8 | 2 |
| 278 | Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 109-109. | 0.8 | 49 |
| 279 | Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9515-9515. | 0.8 | 57 |
| 280 | First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 128-128. | 0.8 | 6 |
| 281 | Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 218-218. | 0.8 | 5 |
| 282 | Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedalscience</i> , 2020, 14, 1148. | 0.6 | 11 |
| 283 | Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC. , 2020, , . | | 0 |
| 284 | Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program. , 2020, , . | | 0 |
| 285 | Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. , 2020, , . | | 1 |
| 286 | Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results. , 2020, , . | | 0 |
| 287 | Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020, 136, 13-14. | 0.6 | 0 |
| 288 | Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557. | 0.6 | 464 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 41-48. | 1.3 | 48 |
| 290 | Biosimilars for breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1015-1021. | 1.4 | 4 |
| 291 | Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. <i>Annals of Oncology</i> , 2019, 30, v55. | 0.6 | 3 |
| 292 | Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. <i>Annals of Oncology</i> , 2019, 30, v790. | 0.6 | 3 |
| 293 | Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. <i>European Journal of Cancer</i> , 2019, 122, 22-41. | 1.3 | 7 |
| 294 | Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22. <i>Annals of Oncology</i> , 2019, 30, v365. | 0.6 | 7 |
| 295 | Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13. | 1.5 | 11 |
| 296 | European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019, 14, 359-365. | 0.8 | 4 |
| 297 | What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 811-822. | 1.1 | 3 |
| 298 | Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2- α positive breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 1-9. | 1.3 | 39 |
| 299 | Are all cyclin-dependent kinases 4/6 inhibitors created equal?. <i>Npj Breast Cancer</i> , 2019, 5, 27. | 2.3 | 85 |
| 300 | Evaluating triptorelin as a treatment option for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1809-1818. | 0.9 | 3 |
| 301 | Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624. | 4.9 | 10 |
| 302 | Safety of Novel Targeted Therapies in Oncology. <i>Drug Safety</i> , 2019, 42, 157-158. | 1.4 | 1 |
| 303 | EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. <i>Breast</i> , 2019, 44, 90-93. | 0.9 | 25 |
| 304 | Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019, 74, 21-28. | 3.4 | 31 |
| 305 | Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target. <i>Annals of Oncology</i> , 2019, 30, iii6-iii7. | 0.6 | 1 |
| 306 | Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605. | 1.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. <i>European Journal of Cancer</i> , 2019, 117, 1-4. | 1.3 | 2 |
| 308 | The evolving landscape of "next-generation" immune checkpoint inhibitors: A review. <i>European Journal of Cancer</i> , 2019, 117, 14-31. | 1.3 | 74 |
| 309 | Systemic Impact of Breast Reconstruction. , 2019, , 769-774. | | 0 |
| 310 | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. <i>Breast Cancer Research</i> , 2019, 21, 71. | 2.2 | 19 |
| 311 | An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 129-138. | 0.4 | 1 |
| 312 | Recent advances in triple negative breast cancer: the immunotherapy era. <i>BMC Medicine</i> , 2019, 17, 90. | 2.3 | 267 |
| 313 | Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 β -MCL-1 Axis. <i>Cancer Cell</i> , 2019, 35, 798-815.e5. | 7.7 | 212 |
| 314 | Defining the immunogram of breast cancer: a focus on clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 383-385. | 1.4 | 14 |
| 315 | Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1347. | 3.4 | 56 |
| 316 | T-cell bispecific antibodies to bypass MHC class I loss in breast cancer. <i>Annals of Oncology</i> , 2019, 30, 877-879. | 0.6 | 9 |
| 317 | Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773. | 0.6 | 78 |
| 318 | Peptide vaccines in early breast cancer. <i>Breast</i> , 2019, 44, 128-134. | 0.9 | 12 |
| 319 | Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b "2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382. | 5.1 | 327 |
| 320 | Homologous recombination deficiency in triple negative breast cancer. <i>Breast</i> , 2019, 45, 15-21. | 0.9 | 58 |
| 321 | WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. <i>Breast Cancer Research</i> , 2019, 21, 123. | 2.2 | 31 |
| 322 | Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. <i>Breast Care</i> , 2019, 14, 373-381. | 0.8 | 8 |
| 323 | Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1034-e1043. | 1.9 | 13 |
| 324 | TRIPLE NEGATIVE ADVANCED BREAST CANCER: BIOLOGY AND RESISTANCE. <i>Breast</i> , 2019, 48, S25. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?. Current Opinion in Oncology, 2019, 31, 469-471. | 1.1 | 1 |
| 326 | RADIOFREQUENCY ABLATION FOR LIVER METASTASES IN THE TREATMENT OF ADVANCED BREAST CANCER. Breast, 2019, 48, S74. | 0.9 | 0 |
| 327 | Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. Current Opinion in Oncology, 2019, 31, 472-479. | 1.1 | 3 |
| 328 | Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology, 2019, 30, 1941-1949. | 0.6 | 155 |
| 329 | Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Annals of Oncology, 2019, 30, ix122. | 0.6 | 13 |
| 330 | Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242. | 0.6 | 123 |
| 331 | A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Review of Clinical Pharmacology, 2019, 12, 9-16. | 1.3 | 4 |
| 332 | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 397-404. | 0.6 | 538 |
| 333 | Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Critical Reviews in Oncology/Hematology, 2019, 133, 171-182. | 2.0 | 93 |
| 334 | Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Safety, 2019, 42, 247-262. | 1.4 | 66 |
| 335 | Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844. | 1.1 | 29 |
| 336 | The role of histone deacetylase inhibitors in metastatic breast cancer. Breast, 2019, 43, 130-134. | 0.9 | 42 |
| 337 | Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 2019, 1168, 9-30. | 0.8 | 114 |
| 338 | Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors. Molecular Cancer Therapeutics, 2019, 18, B057-B057. | 1.9 | 13 |
| 339 | Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Research, 2019, 79, CT183-CT183. | 0.4 | 29 |
| 340 | Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2“negative (HER2““ advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Research, 2019, 79, OT1-03-01-OT1-03-01. | 0.4 | 2 |
| 341 | SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. Journal of Clinical Oncology, 2019, 37, 1000-1000. | 0.8 | 71 |
| 342 | FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.. Journal of Clinical Oncology, 2019, 37, 4511-4511. | 0.8 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. Journal of Clinical Oncology, 2019, 37, 580-580. | 0.8 | 3 |
| 344 | Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. Journal of Clinical Oncology, 2019, 37, 6018-6018. | 0.8 | 34 |
| 345 | Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.. Journal of Clinical Oncology, 2019, 37, 8516-8516. | 0.8 | 9 |
| 346 | Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008. | 0.8 | 75 |
| 347 | Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600E mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. Journal of Clinical Oncology, 2019, 37, 187-187. | 0.8 | 66 |
| 348 | BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology, 2019, 37, 358-358. | 0.8 | 37 |
| 349 | Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52. | | 4 |
| 350 | Abstract P2-08-11: Tumor infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. , 2019, , . | | 0 |
| 351 | Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). , 2019, , . | | 1 |
| 352 | Abstract P6-17-09: Event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting. , 2019, , . | | 2 |
| 353 | Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TReEnd trial. , 2019, , . | | 0 |
| 354 | Toward precision medicine in inflammatory breast cancer. Translational Cancer Research, 2019, 8, S469-S478. | 0.4 | 4 |
| 355 | Targeting the microenvironment in solid tumors. Cancer Treatment Reviews, 2018, 65, 22-32. | 3.4 | 342 |
| 356 | Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?. Lancet Oncology, The, 2018, 19, 434-436. | 5.1 | 3 |
| 357 | A new approach to assess drug sensitivity in cells for novel drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 339-346. | 2.5 | 6 |
| 358 | Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncology, The, 2018, 19, 323-336. | 5.1 | 94 |
| 359 | Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 299-305. | 0.9 | 4 |
| 360 | Adjuvant Chemotherapy. , 2018, , 439-445. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTO. <i>European Journal of Cancer</i> , 2018, 89, 42-48. | 1.3 | 13 |
| 362 | Reply to "The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.. <i>Annals of Oncology</i> , 2018, 29, 281-282. | 0.6 | 3 |
| 363 | Cetuximab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 483-493. | 1.4 | 44 |
| 364 | Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one Atrial. <i>European Journal of Cancer</i> , 2018, 94, 126-137. | 1.3 | 163 |
| 365 | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018, 29, 162-169. | 0.6 | 46 |
| 366 | Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. <i>European Journal of Cancer</i> , 2018, 89, 49-55. | 1.3 | 18 |
| 367 | Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422. | 2.0 | 50 |
| 368 | Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. <i>Annals of Oncology</i> , 2018, 29, viii525. | 0.6 | 3 |
| 369 | Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. <i>Annals of Oncology</i> , 2018, 29, viii606. | 0.6 | 0 |
| 370 | Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. <i>JCO Precision Oncology</i> , 2018, 2, 1-16. | 1.5 | 2 |
| 371 | Cancer Evolution as the New Frontier of Precision Medicine. <i>Handbook of Experimental Pharmacology</i> , 2018, 249, 289-297. | 0.9 | 1 |
| 372 | Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423. | 2.0 | 35 |
| 373 | Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. <i>Annals of Oncology</i> , 2018, 29, viii104. | 0.6 | 2 |
| 374 | Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 125-129. | 2.0 | 19 |
| 375 | Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1385-1393. | 5.1 | 342 |
| 376 | The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49. | 0.9 | 75 |
| 377 | Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. <i>European Journal of Cancer</i> , 2018, 97, 1-6. | 1.3 | 35 |
| 378 | Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2018, 52, 253-258. | 4.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 379 | Talking to patients about biosimilars. <i>Future Oncology</i> , 2018, 14, 2403-2414. | 1.1 | 14 |
| 380 | Inflammatory breast cancer and chest wall disease: The oncologist perspective. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1142-1147. | 0.5 | 6 |
| 381 | Edoxaban for Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 379, 93-96. | 13.9 | 14 |
| 382 | A rude awakening from tumour cells. <i>Nature</i> , 2018, 554, 35-36. | 13.7 | 7 |
| 383 | Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29. | 1.0 | 15 |
| 384 | Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?. <i>Breast</i> , 2018, 41, 133-135. | 0.9 | 8 |
| 385 | Precision trial designer-web: A web-based app to assist in the design of genomics-driven trials. <i>Annals of Oncology</i> , 2018, 29, iii26. | 0.6 | 0 |
| 386 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657. | 0.6 | 891 |
| 387 | The PROMISE to increase precision in adjuvant therapy for early breast cancer: To “Type“-or to “Print“?. <i>Npj Breast Cancer</i> , 2018, 4, 12. | 2.3 | 1 |
| 388 | Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754. | 0.6 | 76 |
| 389 | Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)., 2018, , . | | 1 |
| 390 | Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. <i>Cancer Research</i> , 2018, 78, GS2-06-GS2-06. | 0.4 | 32 |
| 391 | A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3094-3094. | 0.8 | 8 |
| 392 | First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3540-3540. | 0.8 | 35 |
| 393 | Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4032-4032. | 0.8 | 4 |
| 394 | BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4512-4512. | 0.8 | 17 |
| 395 | Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 58-58. | 0.8 | 3 |
| 396 | A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. <i>Oncotarget</i> , 2018, 9, 31709-31718. | 0.8 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2018, 36, 571-571. | 0.8 | 0 |
| 398 | The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Current Oncology Reports, 2017, 19, 1. | 1.8 | 53 |
| 399 | The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258. | 1.3 | 82 |
| 400 | Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology, 2017, 6, e1253654. | 2.1 | 146 |
| 401 | Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 2017, 162, 479-488. | 1.1 | 14 |
| 402 | Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581. | 1.5 | 17 |
| 403 | Breast Cancer Cardio-Oncology. , 2017, , 241-252. | | 0 |
| 404 | Treatment of Hypertension in Patients Receiving Cancer Therapy. , 2017, , 105-123. | | 2 |
| 405 | 3rd ESO"ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33. | 0.6 | 865 |
| 406 | Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. Annals of Oncology, 2017, 28, 441-443. | 0.6 | 8 |
| 407 | Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast, 2017, 34, 89-95. | 0.9 | 15 |
| 408 | SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Medical Oncology, 2017, 34, 75. | 1.2 | 23 |
| 409 | Identification of genetic determinants of breast cancer immunogenicity. Breast, 2017, 32, S1. | 0.9 | 0 |
| 410 | 3rd ESO"ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259. | 0.9 | 171 |
| 411 | The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals of Oncology, 2017, 28, 321-328. | 0.6 | 72 |
| 412 | Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. European Journal of Radiology, 2017, 95, 96-101. | 1.2 | 7 |
| 413 | Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 527-537. | 3.3 | 59 |
| 414 | Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European Journal of Cancer, 2017, 86, 257-265. | 1.3 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. <i>Current Opinion in Oncology</i> , 2017, 29, 428-433. | 1.1 | 2 |
| 416 | Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. <i>Current Opinion in Oncology</i> , 2017, 29, 411-427. | 1.1 | 29 |
| 417 | Entinostat for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 965-971. | 1.9 | 54 |
| 418 | Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe!. <i>Breast</i> , 2017, 36, 86-88. | 0.9 | 2 |
| 419 | Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 152-158. | 0.8 | 14 |
| 420 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-338. | 2.4 | 530 |
| 421 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 225-251. | 2.4 | 469 |
| 422 | How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment. <i>Breast Care</i> , 2017, 12, 136-137. | 0.8 | 0 |
| 423 | Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 164-171. | 1.3 | 7 |
| 424 | Targeting Immune Checkpoint. , 2017, , 781-785. | | 1 |
| 425 | Targeting PI3K/AKT/mTOR Pathway. , 2017, , 787-793. | | 0 |
| 426 | Targeting Genome Instability and DNA Repair. , 2017, , 795-805. | | 0 |
| 427 | Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017, 31, 51-56. | 0.9 | 109 |
| 428 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42. | 2.9 | 920 |
| 429 | Over-using chemotherapy in the adjuvant setting. <i>Breast</i> , 2017, 31, 303-308. | 0.9 | 9 |
| 430 | From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. <i>Breast</i> , 2017, 31, 241-243. | 0.9 | 1 |
| 431 | A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2017, 28, v68. | 0.6 | 3 |
| 432 | G-CSF and G-CSF Biosimilars: A Meta-Analysis of Randomized Clinical Trials in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy. <i>Breast</i> , 2017, 36, S69. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 433 | MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1847-S1848. | 0.5 | 4 |
| 434 | Efficacy and Safety of Platinum and Metronomic Cyclophosphamide in Triple Negative Breast Cancer. <i>Breast</i> , 2017, 36, S47. | 0.9 | 2 |
| 435 | Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. <i>Annals of Oncology</i> , 2017, 28, v50-v51. | 0.6 | 1 |
| 436 | Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi32. | 0.6 | 0 |
| 437 | Precision Trial Designer: A computational tool to assist in the design of genomics-driven trials in oncology. <i>Annals of Oncology</i> , 2017, 28, vii3-vii4. | 0.6 | 0 |
| 438 | Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7. | 0.9 | 65 |
| 439 | Targeting DNA Repair. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 161-180. | 0.9 | 0 |
| 440 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712. | 0.6 | 844 |
| 441 | Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 2320-2328. | 0.8 | 66 |
| 442 | Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2600-2603. | 0.8 | 10 |
| 443 | Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). , 2017, , . | | 3 |
| 444 | Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer. , 2017, , . | | 2 |
| 445 | A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 ⁻) metastatic breast cancer (mBC) (TREnd trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1002. | 0.8 | 14 |
| 446 | Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008. | 0.8 | 99 |
| 447 | Initial efficacy of anti-lymphocyte activation gene-3 (anti-“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-“PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520. | 0.8 | 188 |
| 448 | A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1107-TPS1107. | 0.8 | 1 |
| 449 | Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast Cancer. , 2017, , 719-727. | | 0 |
| 450 | Targeting FGFR Pathway in Breast Cancer. , 2017, , 819-822. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 451 | Integrating Next-Generation Sequencing Data in Trial Design. , 2017, , 823-827. | | 0 |
| 452 | A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, 575-575. | 0.8 | 1 |
| 453 | Arrhythmias and QTc Prolongations. , 2016, , 245-269. | | 0 |
| 454 | Highlights from the 38th SABCS annual meeting, 8th - 12th December 2015, San Antonio, USA. Ecanermedscience, 2016, 10, 618. | 0.6 | 3 |
| 455 | Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP). Annals of Oncology, 2016, 27, iv123. | 0.6 | 0 |
| 456 | Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331. | 1.1 | 100 |
| 457 | Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. Journal of Cardiac Failure, 2016, 22, 465-471. | 0.7 | 54 |
| 458 | Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treatment Reviews, 2016, 50, 205-207. | 3.4 | 50 |
| 459 | Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Ca-A Cancer Journal for Clinicians, 2016, 66, 309-325. | 157.7 | 485 |
| 460 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801. | 1.0 | 1,996 |
| 461 | Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 360-374. | 1.4 | 37 |
| 462 | Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast, 2016, 28, 191-198. | 0.9 | 105 |
| 463 | Being more precise in assessing the value of precision medicine in breast cancer. Breast, 2016, 29, 186-187. | 0.9 | 0 |
| 464 | Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?. European Journal of Surgical Oncology, 2016, 42, 1780-1786. | 0.5 | 26 |
| 465 | A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC). Annals of Oncology, 2016, 27, vi98. | 0.6 | 0 |
| 466 | A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST). Annals of Oncology, 2016, 27, vi119. | 0.6 | 1 |
| 467 | Understanding cognitive processes behind acceptance or refusal of phase I trials. Critical Reviews in Oncology/Hematology, 2016, 100, 69-73. | 2.0 | 21 |
| 468 | Biosimilars: Extrapolation for oncology. Critical Reviews in Oncology/Hematology, 2016, 104, 131-137. | 2.0 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 469 | Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, 157, 120-124. | | 86 |
| 470 | A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Research and Treatment, 2016, 156, 319-330. | 1.1 | 25 |
| 471 | A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 156, 301-310. | 1.1 | 37 |
| 472 | Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy" Circulation, 2016, 133, e363. | 1.6 | 3 |
| 473 | The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. Annals of Oncology, 2016, 27, 6-8. | 0.6 | 90 |
| 474 | Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. , 2016, , . | | 7 |
| 475 | Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified oestrogen receptor positive metastatic breast cancer. , 2016, , . | | 2 |
| 476 | Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer. Cancer Research, 2016, 76, OT3-01-05-OT3-01-05. | 0.4 | 6 |
| 477 | Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). Cancer Research, 2016, 76, P2-08-02-P2-08-02. | 0.4 | 1 |
| 478 | Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2500-2500. | 0.8 | 14 |
| 479 | Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.. Journal of Clinical Oncology, 2016, 34, 2566-2566. | 0.8 | 8 |
| 480 | SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS630-TPS630. | 0.8 | 4 |
| 481 | RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget, 2016, 7, 80901-80915. | 0.8 | 37 |
| 482 | Impact of autoimmune diseases on outcome of patients with early breast cancer. Oncotarget, 2016, 7, 51184-51192. | 0.8 | 10 |
| 483 | Future perspectives in cancer immunotherapy. Annals of Translational Medicine, 2016, 4, 273-273. | 0.7 | 29 |
| 484 | Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study.. Journal of Clinical Oncology, 2016, 34, TPS11615-TPS11615. | 0.8 | 0 |
| 485 | Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer: Clinical perspectives and research opportunities. Translational Cancer Research, 2016, 5, S800-S802. | 0.4 | 0 |
| 486 | HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. Anticancer Research, 2016, 36, 3537-40. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 487 | IN17 CAN IMMUNE-BASED THERAPIES BE THE KEY?. <i>Breast</i> , 2015, 24, S27. | 0.9 | 0 |
| 488 | Immune checkpoint inhibitors with radiotherapy and locoregional treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 445-451. | 1.1 | 39 |
| 489 | Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 452-456. | 1.1 | 17 |
| 490 | Lessons from the first ecancer symposium on angiogenesis in gastric cancer. <i>Ecancermedalscience</i> , 2015, 9, 553. | 0.6 | 0 |
| 491 | Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. <i>BioMed Research International</i> , 2015, 2015, 1-8. | 0.9 | 20 |
| 492 | Immunotherapy of Breast Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 30-43. | 0.1 | 27 |
| 493 | Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015, 41, 61-68. | 3.4 | 48 |
| 494 | Clinical considerations for the development of biosimilars in oncology. <i>MAbs</i> , 2015, 7, 286-293. | 2.6 | 47 |
| 495 | Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. <i>Annals of Oncology</i> , 2015, 26, 682-687. | 0.6 | 51 |
| 496 | QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. <i>Targeted Oncology</i> , 2015, 10, 27-43. | 1.7 | 20 |
| 497 | Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1288-1292. | 0.5 | 30 |
| 498 | Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201. | 2.9 | 205 |
| 499 | Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. <i>Ecancermedalscience</i> , 2015, 9, 518. | 0.6 | 50 |
| 500 | Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291. | 0.6 | 177 |
| 501 | De-escalation attempts for adjuvant trastuzumab: longer beats shorter. <i>Annals of Oncology</i> , 2015, 26, 1275-1276. | 0.6 | 0 |
| 502 | Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015, 24, 263-271. | 0.9 | 13 |
| 503 | PG 4.02 Immune pathways and immunome as a target. <i>Breast</i> , 2015, 24, S8. | 0.9 | 0 |
| 504 | Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2538-2547. | 1.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 505 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546. | 0.6 | 1,449 |
| 506 | Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. <i>Circulation</i> , 2015, 131, 1981-1988. | 1.6 | 1,179 |
| 507 | New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330. | 0.9 | 42 |
| 508 | Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 51-55. | 0.9 | 8 |
| 509 | Mechanisms of anorexia—cachexia syndrome and rationale for treatment with selective ghrelin receptor agonist. <i>Cancer Treatment Reviews</i> , 2015, 41, 793-797. | 3.4 | 27 |
| 510 | Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015, 15, e237-e241. | 1.1 | 13 |
| 511 | Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. , 2015, , 341-361. | | 0 |
| 512 | Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1068-1068. | 0.8 | 4 |
| 513 | Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2590-2590. | 0.8 | 4 |
| 514 | Abstract P4-11-15: Risk stratification within luminal B breast cancer using a second generation prognostic RNA signature. , 2015, , . | | 0 |
| 515 | ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 472. | 0.6 | 2 |
| 516 | ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463. | 0.6 | 26 |
| 517 | Design of the Ideal Trial with Immunotherapeutics. <i>Annals of Oncology</i> , 2014, 25, iv6. | 0.6 | 0 |
| 518 | Optimal adjuvant chemotherapy in breast cancer: selection of agents. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 605-611. | 1.3 | 4 |
| 519 | Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 15-35. | 0.1 | 34 |
| 520 | Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. <i>Pharmaceuticals</i> , 2014, 7, 943-953. | 1.7 | 69 |
| 521 | Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65. | 2.2 | 138 |
| 522 | Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987. | 0.6 | 122 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 523 | “Tu quoque Brute fili mi!” (Julius Caesar, Ides of March, 44 BC). <i>Current Opinion in Oncology</i> , 2014, 26, 543-544. | 1.1 | 0 |
| 524 | Tumor-stroma crosstalk. <i>Current Opinion in Oncology</i> , 2014, 26, 551-555. | 1.1 | 46 |
| 525 | Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”. <i>Toxins</i> , 2014, 6, 914-933. | 1.5 | 62 |
| 526 | Expert perspectives on biosimilar monoclonal antibodies in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 233-239. | 1.1 | 48 |
| 527 | Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. <i>Cancer Treatment Reviews</i> , 2014, 40, 648-655. | 3.4 | 101 |
| 528 | Dendritic cell-based vaccines: clinical applications in breast cancer. <i>Immunotherapy</i> , 2014, 6, 349-360. | 1.0 | 38 |
| 529 | High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75. | 0.9 | 92 |
| 530 | A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289. | 1.3 | 212 |
| 531 | Dinaciclib for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1305-1312. | 1.9 | 42 |
| 532 | Immune approaches to the treatment of breast cancer, around the corner?. <i>Breast Cancer Research</i> , 2014, 16, 204. | 2.2 | 38 |
| 533 | Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014, 16, 205. | 2.2 | 56 |
| 534 | No Link between Breast Cancer and Meningioma: Results from a Large Monoinstitutional Retrospective Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 215-217. | 1.1 | 11 |
| 535 | Reply to L.K. Mell et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1090-1091. | 0.8 | 0 |
| 536 | Early-stage lung cancer—what do the experts recommend?. <i>Annals of Oncology</i> , 2014, 25, 1451-1453. | 0.6 | 1 |
| 537 | Immunoscore breast cancer: TILs remember what they target. <i>Annals of Oncology</i> , 2014, 25, 1455-1456. | 0.6 | 15 |
| 538 | Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 599-610. | 1.9 | 13 |
| 539 | Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014, 25, 611-618. | 0.6 | 359 |
| 540 | WT1, NY-ESO-1 and Prame Expression in Breast Cancer Subtypes. <i>Annals of Oncology</i> , 2014, 25, 117. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1134-TPS1134. | 0.8 | 2 |
| 542 | Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets.. Journal of Clinical Oncology, 2014, 32, 610-610. | 0.8 | 0 |
| 543 | Abstract 627: Immunogenic cell death as novel immune response mechanism to EGFR-targeted therapy in CRC. Cancer Research, 2014, 74, 627-627. | 0.4 | 1 |
| 544 | Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. Anticancer Research, 2014, 34, 6677-83. | 0.5 | 11 |
| 545 | ecancermedalscience. Ecancermedalscience, 2013, 7, 320. | 0.6 | 23 |
| 546 | ecancermedalscience. Ecancermedalscience, 2013, 7, 291. | 0.6 | 0 |
| 547 | ecancermedalscience. Ecancermedalscience, 2013, 7, 299. | 0.6 | 17 |
| 548 | Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology, 2013, 39, 260-265. | 0.5 | 35 |
| 549 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223. | 0.6 | 2,805 |
| 550 | Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast, 2013, 22, 650-656. | 0.9 | 70 |
| 551 | High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. European Journal of Cancer, 2013, 49, 3083-3092. | 1.3 | 14 |
| 552 | Molecular Pathways: Human Leukocyte Antigen G (HLA-G). Clinical Cancer Research, 2013, 19, 5564-5571. | 3.2 | 118 |
| 553 | Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 703-714. | 0.9 | 5 |
| 554 | Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. European Journal of Cancer, 2013, 49, 3588-3597. | 1.3 | 57 |
| 555 | Cytotoxic effect of (1-methyl-1 H-imidazol-2-yl)-methanamine and its derivatives in Pt II complexes on human carcinoma cell lines: A comparative study with cisplatin. Bioorganic and Medicinal Chemistry, 2013, 21, 2379-2386. | 1.4 | 23 |
| 556 | Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. Clinical Cancer Research, 2013, 19, 28-33. | 3.2 | 173 |
| 557 | Best management of locally advanced inoperable breast cancer. European Journal of Cancer, Supplement, 2013, 11, 289-290. | 2.2 | 3 |
| 558 | Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncology, The, 2013, 14, 962-970. | 5.1 | 173 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 559 | Locoregional recurrence in patients with HER2 positive breast cancer. <i>Breast</i> , 2013, 22, 856-862. | 0.9 | 11 |
| 560 | Developing an effective breast cancer vaccine: Challenges to achieving sterile immunity versus resetting equilibrium. <i>Breast</i> , 2013, 22, S96-S99. | 0.9 | 6 |
| 561 | Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2013, 39, 44-50. | 3.4 | 71 |
| 562 | Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. <i>Annals of Oncology</i> , 2013, 24, 1479-1484. | 0.6 | 172 |
| 563 | Immunotherapeutics for breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 602-608. | 1.1 | 27 |
| 564 | HER2 signaling pathway and trastuzumab cardiotoxicity. <i>Future Oncology</i> , 2013, 9, 179-181. | 1.1 | 14 |
| 565 | Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013, 52, 1649-1656. | 0.8 | 56 |
| 566 | End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer "Alliance for Clinical Trials in Oncology" International Society of Geriatric Oncology Position Article. <i>Journal of Clinical Oncology</i> , 2013, 31, 3711-3718. | 0.8 | 267 |
| 567 | Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse) Tj ETQq1 1 0.784314 rgBT /@verlock | | |
| 568 | Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study. , 2013, , . | | 4 |
| 569 | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 617-617. | 0.8 | 0 |
| 570 | ALGA: A cancer patient profiling tool to improve physician-patient communication"An analysis in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9582-9582. | 0.8 | 0 |
| 571 | Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1595-1595. | 0.8 | 0 |
| 572 | Outcome and clinical"biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. <i>Annals of Oncology</i> , 2012, 23, 2884-2890. | 0.6 | 2 |
| 573 | "The only thing I know is that I know nothing" 5-fluorouracil in human milk. <i>Annals of Oncology</i> , 2012, 23, 543-544. | 0.6 | 7 |
| 574 | Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. <i>Annals of Oncology</i> , 2012, 23, 547-555. | 0.6 | 43 |
| 575 | CMF revisited in the 21st century. <i>Annals of Oncology</i> , 2012, 23, 305-311. | 0.6 | 22 |
| 576 | Locoregional recurrence risk after lipofilling in breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 582-588. | 0.6 | 203 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 577 | Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. <i>Annals of Oncology</i> , 2012, 23, 2053-2058. | 0.6 | 101 |
| 578 | Immunotherapy in Breast Cancer – Towards a New Understanding of Both Tumor and Host. <i>Breast Care</i> , 2012, 7, 258-260. | 0.8 | 1 |
| 579 | Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 340-346. | 1.1 | 46 |
| 580 | Risk of Locoregional Recurrence in Patients With False-Negative Frozen Section or Close Margins of Retroareolar Specimen in Nipple-Sparing Mastectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4117-4123. | 0.7 | 57 |
| 581 | Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2012, 23, vii155-vii166. | 0.6 | 667 |
| 582 | Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474. | 0.4 | 25 |
| 583 | New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance. <i>Cancer Treatment Reviews</i> , 2012, 38, 303-310. | 3.4 | 28 |
| 584 | Targeting the subtypes of breast cancer: rethinking investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 191-204. | 1.9 | 3 |
| 585 | Ultrasound-Guided High-Intensity Focused Ultrasound (USgHIFU) Ablation in Pancreatic Metastasis from Renal Cell Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1258-1261. | 0.9 | 9 |
| 586 | Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282. | 1.1 | 61 |
| 587 | Biopsy of liver metastasis for women with breast cancer: Impact on survival. <i>Breast</i> , 2012, 21, 284-288. | 0.9 | 25 |
| 588 | A meta-analysis of receptor status discordance between primary breast cancer and metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546. | 0.8 | 1 |
| 589 | Immunity and autoimmunity in breast cancer. <i>Breast Cancer Research</i> , 2011, 13, . | 2.2 | 0 |
| 590 | Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. <i>European Journal of Surgical Oncology</i> , 2011, 37, 558-562. | 0.5 | 20 |
| 591 | Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233. | 0.6 | 103 |
| 592 | S19 Immunity and autoimmunity: Revising the concepts of response to cancer. <i>Breast</i> , 2011, 20, S7. | 0.9 | 0 |
| 593 | Immunity and autoimmunity: revising the concepts of response to breast cancer. <i>Breast</i> , 2011, 20, S71-S74. | 0.9 | 20 |
| 594 | Autologous fat transplantation in patients with breast cancer: silencing or fueling cancer recurrence?. <i>Breast</i> , 2011, 20, 351-357. | 0.9 | 137 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 595 | The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 369-378. | 1.1 | 13 |
| 596 | Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. <i>Radiologia Medica</i> , 2011, 116, 466-476. | 4.7 | 20 |
| 597 | The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 108-110. | 0.9 | 48 |
| 598 | Cancerâ€™testis antigen expression in triple-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 98-103. | 0.6 | 81 |
| 599 | Nipple-sparing mastectomyâ€™is it worth the risk?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 742-747. | 12.5 | 51 |
| 600 | International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151. | 0.9 | 61 |
| 601 | PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].. <i>Cancer Research</i> , 2011, 71, PD01-02-PD01-02. | 0.4 | 12 |
| 602 | First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11547-e11547. | 0.8 | 1 |
| 603 | Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1056-1056. | 0.8 | 1 |
| 604 | Developing an Effective Breast Cancer Vaccine. <i>Cancer Control</i> , 2010, 17, 183-190. | 0.7 | 36 |
| 605 | Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 277-278. | 2.3 | 1 |
| 606 | High-Intensity Focused Ultrasound Effect in Breast Cancer Nodal Metastasis. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 447-449. | 0.9 | 8 |
| 607 | Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 211-217. | 1.1 | 70 |
| 608 | Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 94-104. | 1.6 | 146 |
| 609 | Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 392-397. | 1.1 | 96 |
| 610 | Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. <i>Breast</i> , 2010, 19, 33-37. | 0.9 | 25 |
| 611 | Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e258-e259. | 0.8 | 2 |
| 612 | The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010, 46, 2926-2935. | 1.3 | 149 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 613 | Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer. , 2010, , . | | 6 |
| 614 | Should liver metastases of breast cancer be biopsied to improve treatment choice?. Journal of Clinical Oncology, 2010, 28, CRA1008-CRA1008. | 0.8 | 17 |
| 615 | Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX).. Journal of Clinical Oncology, 2010, 28, 1078-1078. | 0.8 | 0 |
| 616 | Abstract P6-11-14: Long-Term Disease Control with Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil -ViFuP Regimen-in Metastatic Triple Negative Breast Cancer Patients. , 2010, , . | | 0 |
| 617 | Abstract P6-12-06: Oral Vinorelbine and Capecitabine Plus Bevacizumab in Recurrent Inflammatory Breast Cancer: Gene Profiling and Response to Treatment. , 2010, , . | | 0 |
| 618 | Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5693-5699. | 0.8 | 235 |
| 619 | Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. Urologia Internationalis, 2009, 82, 196-202. | 0.6 | 5 |
| 620 | Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Annals of Oncology, 2009, 20, 498-502. | 0.6 | 9 |
| 621 | Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study. Journal of Chemotherapy, 2009, 21, 687-692. | 0.7 | 7 |
| 622 | Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. Oncology, 2009, 77, 358-365. | 0.9 | 9 |
| 623 | Coagulation Disorders in Patients with Cancer: Nontunneled Central Venous Catheter Placement with US Guidance—A Single-Institution Retrospective Analysis. Radiology, 2009, 253, 249-252. | 3.6 | 25 |
| 624 | Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecanermedicalscience, 2009, 3, 102. | 0.6 | 0 |
| 625 | QTc prolongation assessment in anticancer drug development: Clinical and methodological issues. Ecanermedicalscience, 2009, 3, 130. | 0.6 | 11 |
| 626 | Systemic Therapies for Non-Metastatic Prostate Cancer: Review of the Literature. Onkologie, 2009, 32, 359-363. | 1.1 | 6 |
| 627 | S15 The (last?) word about biomarkers for angiogenesis. Breast, 2009, 18, S6-S7. | 0.9 | 2 |
| 628 | S16 Immunizing against breast cancer: A new swing for an old sword. Breast, 2009, 18, S7. | 0.9 | 0 |
| 629 | Immunizing against breast cancer: A new swing for an old sword. Breast, 2009, 18, S51-S54. | 0.9 | 16 |
| 630 | Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12—'93. Breast Cancer Research and Treatment, 2009, 116, 491-500. | 1.1 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 631 | Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 138-139. | 0.5 | 6 |
| 632 | Vinorelbine, cisplatin, and continuous infusion of 5-fluorouracil (ViFuP regimen) in carcinoma of unknown primary. <i>Journal of Clinical Oncology</i> , 2009, 27, e20682-e20682. | 0.8 | 0 |
| 633 | Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. <i>Supportive Care in Cancer</i> , 2008, 16, 313-314. | 1.0 | 0 |
| 634 | Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 1-7. | 2.0 | 86 |
| 635 | PHASE I/II STUDY OF THE TUMOUR-TARGETING HUMAN L19- IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA. <i>European Urology Supplements</i> , 2008, 7, 307. | 0.1 | 0 |
| 636 | Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , 2008, 44, 494-500. | 1.3 | 44 |
| 637 | Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 16032-16032. | 0.8 | 1 |
| 638 | Cancer therapy and the "broken heart": Decision making during treatment of cancer in patients with left ventricular systolic dysfunction (LVSD). <i>Journal of Clinical Oncology</i> , 2008, 26, 9619-9619. | 0.8 | 0 |
| 639 | Surrogate markers of antiangiogenic therapy in patients with locally advanced breast cancer with lymphangitic spread to the chest wall: Results from a phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. <i>Journal of Clinical Oncology</i> , 2008, 26, 14649-14649. | 0.8 | 0 |
| 640 | Vaccine immunotherapy in breast cancer treatment: promising, but still early. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1225-1241. | 1.1 | 38 |
| 641 | Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epi-doxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1345-1346. | 3.0 | 4 |
| 642 | To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 510-511. | 4.3 | 1 |
| 643 | Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1210-1210. | 3.0 | 4 |
| 644 | Erratum to "A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients" [Lung cancer 54 (2006) 359-364]. <i>Lung Cancer</i> , 2007, 58, 431. | 0.9 | 0 |
| 645 | Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007, 67, 603-604. | 1.2 | 17 |
| 646 | Challenges and prospects of immunotherapy as cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1776, 108-123. | 3.3 | 43 |
| 647 | Immunology and breast cancer: Therapeutic cancer vaccines. <i>Breast</i> , 2007, 16, 20-26. | 0.9 | 22 |
| 648 | S12 Immunity and breast cancer cells: Role of vaccination. <i>Breast</i> , 2007, 16, S3-S4. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 649 | Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007, 15, 1213-1217. | 1.0 | 12 |
| 650 | Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007, 18, 949-954. | 0.7 | 12 |
| 651 | A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 3057-3057. | 0.8 | 7 |
| 652 | 242: Pharmacogenetics Determinants of Anticancer Activity of Intravesical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder. <i>Journal of Urology</i> , 2007, 177, 81-81. | 0.2 | 0 |
| 653 | A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2518-2518. | 0.8 | 0 |
| 654 | Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102. | 0.3 | 15 |
| 655 | A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , 2006, 54, 359-364. | 0.9 | 5 |
| 656 | Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006, 17, 750-762. | 0.6 | 76 |
| 657 | A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 1201-1209. | 0.7 | 11 |
| 658 | In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297. | 2.9 | 43 |
| 659 | Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 1174-1175. | 0.6 | 18 |
| 660 | “Burned out” phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006, 45, 335-336. | 0.8 | 15 |
| 661 | Reply to Letter to the Editor: “Toxic epidermal necrolysis in patients with malignancies”, by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , 2006, 17, 1601-1602. | 0.6 | 2 |
| 662 | What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2006-2006. | 0.8 | 8 |
| 663 | Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. <i>Anticancer Research</i> , 2006, 26, 2375-80. | 0.5 | 3 |
| 664 | Treatment of rectal cancer. <i>New England Journal of Medicine</i> , 2006, 355, 2487; author reply 2487-8. | 13.9 | 0 |
| 665 | Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005, 13, 194-195. | 1.0 | 7 |
| 666 | Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF- β 2) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40. | 1.1 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 667 | Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. <i>Annals of Oncology</i> , 2005, 16, 1094-1099. | 0.6 | 22 |
| 668 | Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 461-462. | 3.0 | 3 |
| 669 | Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6274-6275. | 0.8 | 2 |
| 670 | Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song. <i>Journal of Clinical Oncology</i> , 2005, 23, 7243-7244. | 0.8 | 3 |
| 671 | Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 921-922. | 0.8 | 5 |
| 672 | Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (<i>Ann Oncol</i> 2004; 15: 1543-1550): and in humans?. <i>Annals of Oncology</i> , 2005, 16, 673. | 0.6 | 6 |
| 673 | Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874. | 0.8 | 163 |
| 674 | Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. <i>Breast Cancer Research</i> , 2005, 8, R4. | 2.2 | 67 |
| 675 | Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2520-2520. | 0.8 | 8 |
| 676 | Phase I dose escalation study of SR271425 administered as 24-hour intravenous continuous infusion in patients with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 3116-3116. | 0.8 | 1 |
| 677 | Clinical results and impact on circulating endothelial cells (CEC) of treatment with combinations of interferon- β (I β), thalidomide (T) and celecoxib (C) in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 3193-3193. | 0.8 | 0 |
| 678 | Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. <i>Annals of Oncology</i> , 2004, 15, 590-593. | 0.6 | 52 |
| 679 | Drug-Induced Prolongation of the QT Interval. <i>New England Journal of Medicine</i> , 2004, 350, 2618-2621. | 13.9 | 16 |
| 680 | Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628. | 3.2 | 333 |
| 681 | CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004, 15, 1850. | 0.6 | 1 |
| 682 | Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970. | 0.8 | 31 |
| 683 | Male breast cancer: A special therapeutic problem. Anything new? (Review). <i>International Journal of Oncology</i> , 2004, 24, 663. | 1.4 | 20 |
| 684 | Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310. | 2.0 | 176 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 685 | Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130. | 1.1 | 15 |
| 686 | Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β 2) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004, 22, 672-672. | 0.8 | 1 |
| 687 | Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 8020-8020. | 0.8 | 1 |
| 688 | Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 8020-8020. | 0.8 | 1 |
| 689 | Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF- β 2) in patients with breast cancer who underwent limited or extended surgery. <i>Journal of Clinical Oncology</i> , 2004, 22, 672-672. | 0.8 | 0 |
| 690 | Male breast cancer: a special therapeutic problem. Anything new? (Review). <i>International Journal of Oncology</i> , 2004, 24, 663-70. | 1.4 | 24 |
| 691 | Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. <i>Bulletin Du Cancer</i> , 2004, 91, E273-7. | 0.6 | 0 |
| 692 | Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 428-429. | 0.4 | 21 |
| 693 | Venous thromboembolism and cancer: new issues for an old topic. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 65-80. | 2.0 | 38 |
| 694 | Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Pharmacological Reviews</i> , 2003, 55, 57-103. | 7.1 | 65 |
| 695 | Impact of limited pulmonary function on the management of resectable lung cancer. <i>Lung Cancer</i> , 2003, 41, 71-79. | 0.9 | 25 |
| 696 | Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. <i>Annals of Oncology</i> , 2003, 14, 1477-1483. | 0.6 | 9 |
| 697 | Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. <i>Annals of Oncology</i> , 2003, 14, 803-804. | 0.6 | 18 |
| 698 | Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , 2003, 89, 1403-1404. | 2.9 | 6 |
| 699 | Catheter-Related Bloodstream Infections, Part II: Specific Pathogens and Prevention. <i>Cancer Control</i> , 2003, 10, 79-91. | 0.7 | 3 |
| 700 | Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. <i>Anticancer Research</i> , 2003, 23, 5023-30. | 0.5 | 6 |
| 701 | Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002, 13, 895-902. | 0.6 | 34 |
| 702 | Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 2002, 13, 161-166. | 0.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 703 | Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients. <i>Oncology</i> , 2002, 63, 370-377. | 0.9 | 7 |
| 704 | Catheter-Related Bloodstream Infections, Part I: Pathogenesis, Diagnosis, and Management. <i>Cancer Control</i> , 2002, 9, 513-523. | 0.7 | 7 |
| 705 | Mediastinal lymphadenopathy in a patient with breast cancer. <i>Lancet Oncology</i> , The, 2002, 3, 174. | 5.1 | 2 |
| 706 | Preoperative Chemotherapy in Non-Small-Cell Lung Cancer: Nothing New in N2 Disease. <i>Journal of Clinical Oncology</i> , 2002, 20, 2603-2604. | 0.8 | 1 |
| 707 | Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. <i>Anticancer Research</i> , 2002, 22, 3057-9. | 0.5 | 37 |
| 708 | Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , 2001, 31, 267-270. | 0.9 | 18 |
| 709 | Bone scan had no role in the staging of 765 consecutive operable T1 breast cancer patients without skeletal symptoms. <i>Annals of Oncology</i> , 2001, 12, 724-725. | 0.6 | 11 |
| 710 | Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2. <i>Oncology</i> , 2001, 60, 308-312. | 0.9 | 19 |
| 711 | Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , 2001, 12, 1651-1652. | 0.6 | 49 |
| 712 | Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001, 12, 1553-1559. | 0.6 | 35 |
| 713 | Effect of tamoxifen on GH and IGF-1 serum level in stage II breast cancer patients. <i>Anticancer Research</i> , 2001, 21, 585-8. | 0.5 | 15 |
| 714 | Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. <i>Anticancer Research</i> , 2001, 21, 3015-20. | 0.5 | 2 |
| 715 | GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. <i>Anticancer Research</i> , 2001, 21, 3461-9. | 0.5 | 3 |
| 716 | Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. <i>Anticancer Research</i> , 2001, 21, 4135-9. | 0.5 | 7 |
| 717 | Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. <i>Annals of Oncology</i> , 2000, 11, 1057-1060. | 0.6 | 88 |
| 718 | ACUTE VULVAR VESTIBULITIS OCCURRING DURING CHEMOTHERAPY WITH CRYPTOPHYCIN ANALOGUE LY355703. <i>Obstetrics and Gynecology</i> , 2000, 95, 1030. | 1.2 | 4 |
| 719 | Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000, 11, 821-827. | 0.6 | 26 |
| 720 | Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 33, 129-135. | 2.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 721 | Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?. <i>Annals of Oncology</i> , 2000, 11, 117-118. | 0.6 | 12 |
| 722 | Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LYy355703. <i>Obstetrics and Gynecology</i> , 2000, 95, 1030. | 1.2 | 1 |
| 723 | Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2000, 6, 2393-400. | 3.2 | 16 |
| 724 | Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 1999, 8, 91-6. | 1.1 | 11 |
| 725 | Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. <i>Anticancer Research</i> , 1999, 19, 4571-6. | 0.5 | 3 |
| 726 | P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. <i>Breast Journal</i> , 1998, 4, 270-276. | 0.4 | 1 |
| 727 | 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. <i>Carcinogenesis</i> , 1998, 19, 353-357. | 1.3 | 25 |
| 728 | Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 240-242. | 1.2 | 8 |
| 729 | Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. <i>Anticancer Research</i> , 1997, 17, 2827-30. | 0.5 | 20 |
| 730 | Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. <i>European Journal of Cancer</i> , 1996, 32, 802-806. | 1.3 | 55 |
| 731 | Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. <i>Diseases of the Colon and Rectum</i> , 1996, 39, 1238-1244. | 0.7 | 40 |
| 732 | Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. <i>Carcinogenesis</i> , 1996, 17, 911-916. | 1.3 | 61 |
| 733 | Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , . | 0.5 | 1 |
| 734 | The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046. <i>Investigational New Drugs</i> , 0, , . | 1.2 | 8 |
| 735 | Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , . | 3.4 | 51 |